Evaluation of a Set of Refolded Recombinant Antigens for Serodiagnosis of Human Fascioliasis

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2018 Oct 4

PMID 30281608

Citations 2

Authors

Abolfazl Mirzadeh

Asiyeh Yoosefy

Elham Kazemirad

Zahra Barati

Majid Golkar

Jalal Babaie

Farid Jafarihaghighi

Zarrintaj Valadkhani

Affiliations

Soon will be listed here.

Abstract

Diagnosis of fascioliasis with high sensitivity and specificity antigens play a vital role in the management of the disease. Majority of commercial serological tests use F. hepatica native antigens and indicate wide diversities in test accuracy. Nowadays, recombinant antigens have been introduced as diagnostic reagents offer better test standardization. A combination of highly pure recombinant antigens associated with correct folding will leads to improve specificity and sensitivity of ELISA for diagnosis of Fascioliasis. In this article, Fasciola hepatica saposin-like protein 2 (SAP-2), ferritin protein (Ftn-1) and leucine aminopeptidase (LAP) recombinant antigens were considered as tools for the detection of F. hepatica immunoglobulin G antibodies in persons with chronic human fasciolasis. The recombinant antigens were obtained as fusion proteins, expressed in Escherichia coli and purified by immobilized metal affinity chromatography (IMAC). The refolding processes of denatured recombinant proteins were performed using dialysis method in the presence of chemical additives, and reduced/oxidized glutathione (in vitro). The immunoreactivity of the recombinant antigens was assessed individually and in a combination compared with excretory/secretory antigen (E/S) in an enzyme-linked immunosorbent assay (ELISA) test. The experiments were optimized using 213 serum samples from humans, including patients with chronic fascioliasis, patients with other parasitic diseases, and healthy subjects. The results indicated 95% sensitivity and 98% specificity for rtFhSAP-2, 96% sensitivity and 91% specificity for E/S, 80% and 83.3% for rtFhFtn-1, 84% and 88% for FhLAP, and also, 96% and 95% for combination of recombinant antigens, respectively. In conclusion, the results of this investigation showed that rtFhSAP-2 with the highest specificity and acceptable sensitivity has a considerable superiority compared to mentioned antigens and even in combination with these antigens in serodiagnosis of human fascioliasis.

Citing Articles

Recent Developments in Recombinant Proteins for Diagnosis of Human Fascioliasis.

Mirzadeh A, Jafarihaghighi F, Kazemirad E, Sabzevar S, Tanipour M, Ardjmand M Acta Parasitol. 2020; 66(1):13-25.

PMID: 32974849 DOI: 10.1007/s11686-020-00280-5.

Immunoproteomic Approach of Extracellular Antigens From Species Reveals Exclusive B-Cell Epitopes.

Moreira A, Oliveira M, Souza Silva L, Inacio M, Bailao A, Parente-Rocha J Front Microbiol. 2020; 10:2968.

PMID: 32117076 PMC: 7015227. DOI: 10.3389/fmicb.2019.02968.

References

Espino A, Morales A, Delgado B, Rivera F, Figueroa O, Suarez E . Partial immunity to Fasciola hepatica in mice after vaccination with FhSAP2 delivered as recombinant protein or DNA construct. Ethn Dis. 2010; 20(1 Suppl 1):S1-17-23. PMC: 3260556. View

Esteban J, Bargues M . Epidemiology of human fascioliasis: a review and proposed new classification. Bull World Health Organ. 1999; 77(4):340-6. PMC: 2557647. View

Jayaraj R, Hales B, Viberg L, Pizzuto S, Holt D, Rolland J . A diagnostic test for scabies: IgE specificity for a recombinant allergen of Sarcoptes scabiei. Diagn Microbiol Infect Dis. 2011; 71(4):403-7. DOI: 10.1016/j.diagmicrobio.2011.09.007. View

Gonzales Santana B, Dalton J, Vasquez Camargo F, Parkinson M, Ndao M . The diagnosis of human fascioliasis by enzyme-linked immunosorbent assay (ELISA) using recombinant cathepsin L protease. PLoS Negl Trop Dis. 2013; 7(9):e2414. PMC: 3777859. DOI: 10.1371/journal.pntd.0002414. View

Figueroa-Santiago O, Delgado B, Espino A . Fasciola hepatica saposin-like protein-2-based ELISA for the serodiagnosis of chronic human fascioliasis. Diagn Microbiol Infect Dis. 2011; 70(3):355-61. PMC: 3260655. DOI: 10.1016/j.diagmicrobio.2011.03.016. View

Attallah A, Bughdadi F, M El-Shazly A, Ismail H . Immunodetection of Fasciola gigantica circulating antigen in sera of infected individuals for laboratory diagnosis of human fascioliasis. Clin Vaccine Immunol. 2013; 20(10):1569-77. PMC: 3807196. DOI: 10.1128/CVI.00305-13. View

Espino A, Hillyer G . Molecular cloning of a member of the Fasciola hepatica saposin-like protein family. J Parasitol. 2003; 89(3):545-52. DOI: 10.1645/GE-3113. View

Gottstein B, Schneeberger M, Boubaker G, Merkle B, Huber C, Spiliotis M . Comparative assessment of ELISAs using recombinant saposin-like protein 2 and recombinant cathepsin L-1 from Fasciola hepatica for the serodiagnosis of human Fasciolosis. PLoS Negl Trop Dis. 2014; 8(6):e2860. PMC: 4055579. DOI: 10.1371/journal.pntd.0002860. View

Mirzadeh A, Saadatnia G, Golkar M, Babaie J, Noordin R . Production of refolded Toxoplasma gondii recombinant SAG1-related sequence 3 (SRS3) and its use for serodiagnosis of human toxoplasmosis. Protein Expr Purif. 2017; 133:66-74. DOI: 10.1016/j.pep.2017.03.001. View

10.

Sahdev S, Khattar S, Saini K . Production of active eukaryotic proteins through bacterial expression systems: a review of the existing biotechnology strategies. Mol Cell Biochem. 2007; 307(1-2):249-64. DOI: 10.1007/s11010-007-9603-6. View

11.

Mas-Coma S, Angles R, Esteban J, Bargues M, Buchon P, Franken M . The Northern Bolivian Altiplano: a region highly endemic for human fascioliasis. Trop Med Int Health. 1999; 4(6):454-67. DOI: 10.1046/j.1365-3156.1999.00418.x. View

12.

ONeill S, Parkinson M, Strauss W, Angles R, Dalton J . Immunodiagnosis of Fasciola hepatica infection (fascioliasis) in a human population in the Bolivian Altiplano using purified cathepsin L cysteine proteinase. Am J Trop Med Hyg. 1998; 58(4):417-23. DOI: 10.4269/ajtmh.1998.58.417. View

13.

Rokni M, Massoud J, ONeill S, Parkinson M, Dalton J . Diagnosis of human fasciolosis in the Gilan province of Northern Iran: application of cathepsin L-ELISA. Diagn Microbiol Infect Dis. 2002; 44(2):175-9. DOI: 10.1016/s0732-8893(02)00431-5. View

14.

Middelberg A . Preparative protein refolding. Trends Biotechnol. 2002; 20(10):437-43. DOI: 10.1016/s0167-7799(02)02047-4. View

15.

Acosta D, Cancela M, Piacenza L, Roche L, Carmona C, Tort J . Fasciola hepatica leucine aminopeptidase, a promising candidate for vaccination against ruminant fasciolosis. Mol Biochem Parasitol. 2008; 158(1):52-64. DOI: 10.1016/j.molbiopara.2007.11.011. View

16.

Espino A, Hillyer G . A novel Fasciola hepatica saposinlike recombinant protein with immunoprophylactic potential. J Parasitol. 2004; 90(4):876-9. DOI: 10.1645/GE-215R. View

17.

Perez-Sanchez R, Ramajo-Hernandez A, Ramajo-Martin V, Oleaga A . Proteomic analysis of the tegument and excretory-secretory products of adult Schistosoma bovis worms. Proteomics. 2006; 6 Suppl 1:S226-36. DOI: 10.1002/pmic.200500420. View

18.

Patil N, Tailhades J, Hughes R, Separovic F, Wade J, Hossain M . Cellular disulfide bond formation in bioactive peptides and proteins. Int J Mol Sci. 2015; 16(1):1791-805. PMC: 4307334. DOI: 10.3390/ijms16011791. View

19.

Okumura M, Saiki M, Yamaguchi H, Hidaka Y . Acceleration of disulfide-coupled protein folding using glutathione derivatives. FEBS J. 2011; 278(7):1137-44. DOI: 10.1111/j.1742-4658.2011.08039.x. View

20.

Kuerpick B, Schnieder T, Strube C . Evaluation of a recombinant cathepsin L1 ELISA and comparison with the Pourquier and ES ELISA for the detection of antibodies against Fasciola hepatica. Vet Parasitol. 2012; 193(1-3):206-13. DOI: 10.1016/j.vetpar.2012.11.021. View